COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
21 Jul 2020
Historique:
received: 01 06 2020
revised: 16 07 2020
accepted: 17 07 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 4 8 2020
Statut: epublish

Résumé

Coronavirus 2 (CoV) Severe Acute Respiratory Syndrome (SARS-CoV2) is causing a highly infectious pandemic pneumonia. Coronaviruses are positive sense single-stranded RNA viruses that infect several animal species, causing symptoms that range from those similar to the common cold to severe respiratory syndrome. The Angiotensin Converting Enzyme 2 (ACE2) is the SARS-CoV2 functional receptor. Measures are currently undertaken worldwide to control the infection to avoid disruption of the social and economic equilibrium, especially in countries with poor healthcare resources. In a guarded optimistic view, we hope that the undertaken preventive and treatment measures will at least contribute to contain viral diffusion, attenuate activity, or even eliminate SARS-CoV2. In this review, we discuss emerging perspectives for prevention/treatment of COVID-19 infection. In addition to vaccines under development, passive immunization is an open opportunity since patients develop neutralizing antibodies. A full spectrum of potential drugs for COVID-19 infections could in turn affect virus binding or enzymatic activities involved in viral replication and transcription. Furthermore, clinical trials are currently evaluating the safety and efficacy of anti-inflammatory drugs, such as tocilizumab. Bioinformatics may allow characterization of specific CD8+ and CD4+ T cell responses; thus, CoV2 T cells' frequency can be correlated with the disease severity and outcome. Combinatorial antibody phage display may be empowered to identify the immune repertoire of CoV2-specific neutralizing antibodies.

Identifiants

pubmed: 32708112
pii: ijms21145145
doi: 10.3390/ijms21145145
pmc: PMC7404132
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Antiviral Agents 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Peptidyl-Dipeptidase A EC 3.4.15.1
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Front Immunol. 2018 Dec 21;9:3004
pubmed: 30622532
Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134
pubmed: 32119647
Cell Res. 2013 Feb;23(2):300-2
pubmed: 23208422
Emerg Microbes Infect. 2018 Mar 21;7(1):41
pubmed: 29568066
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16;43(0):E014
pubmed: 32061198
Cell Biosci. 2020 Mar 16;10:40
pubmed: 32190290
Diabetes Metab Res Rev. 2011 Mar;27(3):216-29
pubmed: 21309048
Emerg Infect Dis. 2005 Jul;11(7):1016-20
pubmed: 16022774
J Virol. 2013 Jul;87(14):8017-28
pubmed: 23678171
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
EMBO J. 1994 May 1;13(9):2236-43
pubmed: 7514533
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670
pubmed: 32196083
Int Immunopharmacol. 2020 Aug;85:106688
pubmed: 32544867
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
J Med Virol. 2020 Apr 15;:
pubmed: 32293713
Emerg Microbes Infect. 2020 Dec;9(1):275-277
pubmed: 32005086
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
J Exp Med. 2005 Dec 5;202(11):1575-85
pubmed: 16330816
Emerg Microbes Infect. 2019;8(1):516-530
pubmed: 30938227
Front Immunol. 2019 Dec 03;10:2776
pubmed: 31849959
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Nature. 2008 Dec 4;456(7222):658-62
pubmed: 18820679
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
EMBO J. 1998 Nov 2;17(21):6230-40
pubmed: 9799232
Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18
pubmed: 32134278
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Am J Hematol. 2013 Dec;88(12):1035-40
pubmed: 23907744
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Front Immunol. 2020 May 15;11:1061
pubmed: 32574262
J Appl Lab Med. 2020 May 19;:
pubmed: 32428207
Emerg Microbes Infect. 2020 Dec;9(1):542-544
pubmed: 32148172
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Biosci Trends. 2020 Mar 16;14(1):69-71
pubmed: 31996494
Chin J Integr Med. 2020 Apr;26(4):243-250
pubmed: 32065348
Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64
pubmed: 14651994
Nat Rev Rheumatol. 2020 Mar;16(3):155-166
pubmed: 32034323
Nature. 2020 Jul 30;:
pubmed: 32731258
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
PLoS Negl Trop Dis. 2017 Dec 21;11(12):e0006000
pubmed: 29267278
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
Science. 2020 Jan 31;367(6477):492-493
pubmed: 32001631
Cell. 2020 Aug 6;182(3):685-712.e19
pubmed: 32645325
Immunology. 2020 Jul;160(3):223-232
pubmed: 32460358
JAMA. 2020 Mar 27;:
pubmed: 32219428
J Biol Chem. 2016 Apr 22;291(17):9218-32
pubmed: 26953343
Sci Adv. 2019 Apr 10;5(4):eaav4580
pubmed: 30989115
JAMA. 2020 Feb 7;:
pubmed: 32031570
Nat Rev Microbiol. 2013 Dec;11(12):836-48
pubmed: 24217413
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Expert Opin Ther Pat. 2013 Oct;23(10):1337-48
pubmed: 23905913
Curr Opin Anaesthesiol. 2015 Apr;28(2):227-36
pubmed: 25590467
Chembiochem. 2020 Mar 2;21(5):730-738
pubmed: 32022370
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Mol Cell Probes. 2002 Jun;16(3):223-9
pubmed: 12144774
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
JAMA. 2020 Jun 3;:
pubmed: 32492084
J Rheumatol. 1997 Jan;24(1):55-60
pubmed: 9002011
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Am J Pathol. 2020 Aug;190(8):1680-1690
pubmed: 32473109
Trials. 2020 Jun 8;21(1):499
pubmed: 32513308
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Crit Care. 2020 Mar 16;24(1):91
pubmed: 32178711
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
Int J Antimicrob Agents. 2020 Apr;55(4):105944
pubmed: 32179150
Drug Des Devel Ther. 2018 Dec 19;13:57-70
pubmed: 30587928
Hum Vaccin Immunother. 2020 Jun 2;16(6):1232-1238
pubmed: 32186952
N Engl J Med. 2020 May 7;382(19):1851-1852
pubmed: 32187463
Clin Chem Lab Med. 2020 Jun 25;58(7):1063-1069
pubmed: 32191623
Microbiol Spectr. 2014 Dec;2(6):
pubmed: 26104444
Intern Emerg Med. 2020 Aug;15(5):819-824
pubmed: 32468508
Int J Antimicrob Agents. 2016 Oct;48(4):349-52
pubmed: 27546219
Biochem Biophys Res Commun. 2020 Feb 17;:
pubmed: 32081428
J Immunol. 2015 May 1;194(9):4089-93
pubmed: 25821216
J Med Virol. 2020 May;92(5):495-500
pubmed: 32022276
Nature. 2004 Apr 1;428(6982):561-4
pubmed: 15024391
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466
JAMA. 2020 Mar 11;:
pubmed: 32159775
Drug Discov Today. 2020 Apr;25(4):668-688
pubmed: 32006468
Diagnostics (Basel). 2020 Mar 18;10(3):
pubmed: 32197339

Auteurs

Alessandra Fierabracci (A)

Infectivology and Clinical Trials Research Department, Children's Hospital Bambino Gesù, 00146 Rome, Italy.

Andrea Arena (A)

Infectivology and Clinical Trials Research Department, Children's Hospital Bambino Gesù, 00146 Rome, Italy.

Paolo Rossi (P)

Infectivology and Clinical Trials Research Department, Children's Hospital Bambino Gesù, 00146 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH